WallStreetZenWallStreetZen

NASDAQ: SRPT
Sarepta Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Sarepta Therapeutics revenue was $1.90B for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $658.4M, up 40.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, SRPT annual revenue was $1.9B, with 53% growth year-over-year.

SRPT past revenue growth

How has SRPT's revenue growth performed historically?

Company
52.97%
Industry
511.06%
Market
20.87%
SRPT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SRPT's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SRPT's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SRPT revenue history

Current Revenue
$1.9B
Current Earnings
$235.2M
Current Profit Margin
12.4%

Be the first to know when SRPT announces revenue.

SRPT Revenue History By Year

SRPT Yearly RevenueSRPT RevenueSRPT ChangeSRPT Revenue Growth
2024-12-31$1.90B$658.64M+52.97%
2023-12-31$1.24B$310.32M+33.26%
2022-12-31$933.01M$231.13M+32.93%
2021-12-31$701.89M$161.79M+29.96%
2020-12-31$540.10M$159.27M+41.82%
2019-12-31$380.83M$79.80M+26.51%
2018-12-31$301.03M$146.45M+94.74%
2017-12-31$154.58M$149.16M+2,751.58%
2016-12-31$5.42M$4.17M+332.64%
2015-12-31$1.25M-$8.50M-87.16%
2014-12-31$9.76M-$4.46M-31.38%
2013-12-31$14.22M-$23.11M-61.91%
2012-12-31$37.33M-$9.66M-20.56%
2011-12-31$46.99M$17.57M+59.72%
2010-12-31$29.42M$11.84M+67.30%
2009-12-31$17.59M-$3.67M-17.28%
2008-12-31$21.26M$10.27M+93.52%
2007-12-31$10.99M$10.87M+9,428.06%
2006-12-31$115.29k-$4.67M-97.59%
2005-12-31$4.78M$4.35M+1,011.31%
2004-12-31$430.46k-$539.41k-55.62%
2003-12-31$969.87k$133.08k+15.90%
2002-12-31$836.78k$130.68k+18.51%
2001-12-31$706.10k-$591.24k-45.57%
2000-12-31$1.30M$1.28M+7,520.64%
1999-12-31$17.02k-$103.33k-85.85%
1998-12-31$120.35k$106.01k+738.98%
1997-12-31$14.35k-$12.88k-47.31%
1996-12-31$27.23kN/AN/A

1 of 2

Sarepta Therapeutics Revenue FAQ

What was SRPT's revenue last quarter?

On Invalid Date, Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 2024 revenue of $658.41 million up 65.94% year over year. In the same quarter last year, Sarepta Therapeutics's revenue was $396.78 million.

What was Sarepta Therapeutics's revenue in 2024?

Sarepta Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $1.90 billion, a 52.97% increase year over year.

How much does Sarepta Therapeutics make in a day?

Based on Sarepta Therapeutics annual revenue for the past five years, SRPT makes an average of $2,915,240.55 per day.

What was Sarepta Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Sarepta Therapeutics's revenue has grown 52.97% year over year. This is 458.09 percentage points lower than the US Biotechnology industry revenue growth rate of 511.06%. Sarepta Therapeutics's revenue in the past year totaled $1.90 billion.

How much does Sarepta Therapeutics make in a year?

Sarepta Therapeutics's revenue by year for the past five years is:
  • Sarepta Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $1.90 billion, a 52.97% increase year over year.
  • Sarepta Therapeutics's annual revenue for Dec 31, 2023 was $1.24 billion, a 33.26% increase from 2022.
  • Sarepta Therapeutics's annual revenue for 2022 was $933.01 million, a 32.93% increase from 2021.
  • Sarepta Therapeutics's annual revenue for 2021 was $701.89 million, a 29.96% increase from 2020.
  • Sarepta Therapeutics's annual revenue for 2020 was $540.10 million, a 41.82% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.